Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
28 hedge funds and large institutions have $758K invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 7 closing their positions.
17% less capital invested
Capital invested by funds: $913K → $758K (-$155K)
18% less funds holding
Funds holding: 34 → 28 (-6)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$43.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$36.7K |
| 2 |
SC
Shay Capital
New York
|
-$13.4K |
| 3 |
LC
Lindbrook Capital
Calabasas,
California
|
-$2.93K |
| 4 |
Jane Street
New York
|
-$2.13K |
| 5 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$2.1K |
DNA.WS Hedge Fund Activity: Q1 2024 in Review
28 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q1 2024, worth a combined $758K — down 17% from $913K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DNA.WS and 1 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Cowen and Company, adding an estimated $43.4K. The largest seller was Ionic Capital Management, exiting entirely with an estimated $36.7K sold.
- 28 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q1 2024, down from 34 in Q4 2023.
- Funds reported $758K of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q1 2024, down 17% quarter-over-quarter.
- 1 fund opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q1 2024 and 7 closed out, a net change of -6 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q1 2024 was Cowen and Company, an estimated $43.4K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q1 2024 was Ionic Capital Management, an estimated $36.7K sold.
Based on aggregated 13F filings for Q1 2024.